Dasgupta Ramanuj, Perrimon Norbert
Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Oncogene. 2004 Nov 1;23(51):8359-65. doi: 10.1038/sj.onc.1208028.
The completion of whole-genome sequencing of various model organisms and the recent explosion of new technologies in the field of Functional Genomics and Proteomics is poised to revolutionize the way scientists identify and characterize gene function. One of the most significant advances in recent years has been the application of RNA interference (RNAi) as a means of assaying gene function. In the post-genomic era, advances in the field of cancer biology will rely upon the rapid identification and characterization of genes that regulate cell growth, proliferation, and apoptosis. Significant efforts are being directed towards cancer therapy and devising efficient means of selectively delivering drugs to cancerous cells. In this review, we discuss the promise of integrating genome-wide RNAi screens with proteomic approaches and small-molecule chemical genetic screens, towards improving our ability to understand and treat cancer.
各种模式生物全基因组测序的完成，以及功能基因组学和蛋白质组学领域近期新技术的激增，有望彻底改变科学家识别和表征基因功能的方式。近年来最重要的进展之一是将RNA干扰（RNAi）用作检测基因功能的手段。在后基因组时代，癌症生物学领域的进展将依赖于对调控细胞生长、增殖和凋亡的基因进行快速识别和表征。目前正投入大量精力进行癌症治疗，并设计出将药物选择性地递送至癌细胞的有效方法。在本综述中，我们讨论了将全基因组RNAi筛选与蛋白质组学方法及小分子化学遗传学筛选相结合的前景，以提高我们理解和治疗癌症的能力。
